FindTrial
Sign In

Serum lactate dehydrogenase-to-albumin ratio (LAR) as a preoperative biomarker for predicting microvascular invasion in hepatocellular carcinoma

Serum lactate dehydrogenase-to-albumin ratio (LAR) as a preoperative biomarker for predicting microvascular invasion in hepatocellular carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500113240
Enrollment
Unknown
Registered
2025-11-26
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

High LAR:none
Low LAR:none

Sponsors

The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University(Huai'an First People's Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) The diagnosis of hepatocellular carcinoma is confirmed through pathological examination. (2) The follow-up data and clinical pathological features are complete. (3) Patients with hepatocellular carcinoma received surgical treatment.

Exclusion criteria

Exclusion criteria: (1) Incomplete data. (2) No surgical treatment received. (3) The tumor has metastasized to distant sites.

Design outcomes

Primary

MeasureTime frame
Ratio of lactate dehydrogenase to albumin;Microvascular invasion, MVI;—

Secondary

MeasureTime frame
Length of stay;Edmondson-Steiner grading;TNM staging system ;—

Countries

China

Contacts

Public ContactFuzhen Qi

The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University(Huai'an First People's Hospital)

2412911869@qq.com+86 158 6175 5430

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026